-+ 0.00%
-+ 0.00%
-+ 0.00%

Cipla wins US FDA approval for generic Advair Diskus across three strengths

PUBT·07/28/2026 12:01:16
Listen to the news
Cipla wins US FDA approval for generic Advair Diskus across three strengths
  • Cipla received US FDA clearance for its generic Advair Diskus inhalation powder across all three strengths.
  • The drug targets asthma, COPD; IQVIA pegs the US market at about $908 million.
  • Cipla flagged the clearance as its first US-made dry powder inhaler approval from its US manufacturing network.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cipla Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607280800PR_NEWS_USPR_____IO13564) on July 28, 2026, and is solely responsible for the information contained therein.